1.Systematic review and Meta-analysis of efficacy and safety of Kushen Gelatum combined with antibiotics in treatment of bacterial vaginosis.
Ju-Wen ZHANG ; Li-Na ZHANG ; Ling XIONG ; Xu-Dong ZHANG ; Xue BAI ; Wei CHEN
China Journal of Chinese Materia Medica 2023;48(21):5946-5956
This study aims to systematically evaluate the clinical efficacy and safety of Kushen Gelatum combined with antibiotics for treating bacterial vaginosis. The randomized controlled trial(RCT) of Kushen Gelatum for treating bacterial vaginosis were retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, and Cochrane Library with the time interval from inception to January 2023. Data were extracted from the included RCT by 2 investigators, including the sample size, characteristics of patients, interventions and controls, outcome indicators, and adverse effects. The Cochrane collaboration network's bias risk assessment tool was used for methodolo-gical quality evaluation of the included trials. RevMan 5.4 was employed to perform the Meta-analysis. A total of 19 RCTs were inclu-ded, involving 1 980 patients with bacterial vaginosis. Meta-analysis showed that, compared with nitroimidazoles alone, Kushen Gelatum + nitroimidazoles improved the total response rates in terms of clinical symptoms and laboratory tests(RR=1.24, 95%CI[1.13, 1.36], P<0.000 01), laboratory tests(RR=1.16, 95%CI[1.06, 1.26], P=0.000 9), and clinical symptoms(RR=1.26, 95%CI[1.08, 1.46], P=0.003), and reduced the leukocyte esterase positive rate(RR=0.29, 95%CI[0.17, 0.48], P<0.000 01) and the recurrence rate(RR=0.37, 95%CI[0.23, 0.58], P<0.000 1). Compared with lincomycin antibiotics(clindamycin) alone, Kushen Gelatum + lincomycin antibiotics(clindamycin) improved the total response rates in terms of clinical symptoms and laboratory tests(RR=1.18, 95%CI[1.06, 1.31], P=0.003) and laboratory tests(RR=1.27, 95%CI[1.04, 1.54], P=0.02), reduced the recurrence rate(RR=0.20, 95%CI[0.05, 0.75], P=0.02), and shortened the time to relief of burning sensation(MD=-1.70, 95%CI[-2.15,-1.26], P<0.000 01), vaginal itching(MD=-0.82, 95%CI[-1.30,-0.34], P=0.000 8), and abnormal leucorrhea(MD=-1.52, 95%CI[-1.98,-1.06], P<0.000 01). Compared with nitroimidazoles + probiotics, Kushen Gelatum + nitroimidazoles + probiotics improved the total response rate in terms of clinical symptoms and laboratory tests(RR=1.18, 95%CI[1.02, 1.36], P=0.03) and reduced the recurrence rate(RR=0.27, 95%CI[0.09, 0.76], P=0.01). Kushen Gelatum combined with antibiotics demonstrates a potential therapeutic effect on bacterial vaginosis, whereas the number and quality of the relevant clinical studies remain to be improved. The process of clinical trial should be standardized to improve the quality of evidence, so as to provide strong evidence to guide the application of Kushen Gelatum in clinical practice.
Female
;
Humans
;
Anti-Bacterial Agents/adverse effects*
;
Clindamycin/adverse effects*
;
Vaginosis, Bacterial/chemically induced*
;
Nitroimidazoles/adverse effects*
7.Research progress in the relationship between childhood wheezing and bacteria.
Feng-Xia DING ; Jian LUO ; Zhou FU
Chinese Journal of Contemporary Pediatrics 2015;17(5):528-532
Wheezing is one of the most common clinical manifestations of childhood respiratory diseases, mainly associated with virus infection. Recent years, bacteria colonization and its infection are reported to involve in childhood wheezing, especially in infantile wheezing. However, the bacteria flora in the airway is only a phenomenon or a reason to induce some childhood wheezing, and its roles, as well as the mechanism in the development of wheezing remain unknown. This article summarizes the research progress in the relationship between childhood wheezing and bacteria and in the possible mechanisms of childhood wheezing caused by bacteria.
Anti-Bacterial Agents
;
adverse effects
;
Bacterial Infections
;
complications
;
Humans
;
Respiratory Sounds
;
etiology
;
Respiratory Tract Infections
;
complications
8.Mechanisms and management of drug induced liver injury in children.
Chinese Journal of Pediatrics 2014;52(8):583-585
Anti-Bacterial Agents
;
adverse effects
;
Anti-Infective Agents
;
adverse effects
;
Anti-Inflammatory Agents
;
adverse effects
;
Biomarkers
;
blood
;
Chemical and Drug Induced Liver Injury
;
diagnosis
;
epidemiology
;
Child
;
Drug-Related Side Effects and Adverse Reactions
;
Humans
;
Liver
;
drug effects
;
metabolism
;
pathology
;
Pediatrics
;
Risk Factors
9.A Case of Immune Hemolytic Anemia Induced by Ceftizoxime and Cefobactam (Sulbactam/Cefoperazone).
Eun Jung BAEK ; Sungsil LEE ; Sinyoung KIM ; Hyun Kyung CHOI ; Hyun Ok KIM
The Korean Journal of Laboratory Medicine 2009;29(6):578-584
Simultaneous drug-induced immune hemolytic anemia (DIIHA) caused by multiple drugs is rare. We report a case of a patient who developed DIIHA caused by 2 drugs. The patient's serum exhibited agglutination of ceftizoxime- or sulbactam-coated red blood cells (RBCs; via a drug-adsorption mechanism) and of uncoated RBCs in the presence of sulbactam (via an immune-complex mechanism). Although ceftizoxime is known to exhibit a positive reaction by an immune-complex method with or without reactivity with drug-coated RBCs, this patient's antibodies were reactive only against drug-coated RBCs. On the other hand, sulbactam, which is known to cause hemolytic anemia by nonimmunologic protein adsorption, exhibited positive reactions in tests with both drug-coated RBCs and in the presence of sulbactam. This is the first report of DIIHA due to a sulbactam-cefoperazone combination and the fourth report of DIIHA due to ceftizoxime. Owing to the patient's complicated laboratory results, DIIHA was suspected only at a late stage. We propose that for the prompt diagnosis of DIIHA, tests for all possible causative drugs should be conducted by 2 methods.
Anemia, Hemolytic/chemically induced/*diagnosis/immunology
;
Anti-Bacterial Agents/*adverse effects
;
Cefoperazone/*adverse effects
;
Ceftizoxime/*adverse effects
;
Erythrocytes/chemistry/metabolism
;
Female
;
Humans
;
Middle Aged
;
Sulbactam/*adverse effects